Optimization of the use of B-type natriuretic peptide levels for risk stratification at discharge in elderly patients with decompensated heart failure

被引:20
作者
Cournot, Maxime [1 ,2 ]
Mourre, Fabien [1 ]
Castel, Fabienirie [3 ]
Ferrieres, Jean [2 ]
Destrac, Sylvain [1 ]
机构
[1] Ctr Hosp Val Ariege, Dept Cardiol, Foix, France
[2] INSERM, U558, Cardiovasc Epidemiol Unit, F-31073 Toulouse, France
[3] Ctr Hosp Val Ariege, Dept Gerontol, Foix, France
关键词
D O I
10.1016/j.ahj.2008.01.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background In elderly patients hospitalized for decompensated heart failure, B-type natriuretic peptide (BNP) levels at discharge and the change in BNP during hospitalization may provide different information and may need to be taken into account simultaneously to best reflect the response to therapy. The aim of this study was to determine whether the most accurate risk stratification is obtained using BNP level after stabilization on treatment, the change in BNP under optimal treatment, or a combination of both markers. Methods This prospective cohort study included 157 consecutive patients aged >= 70 (mean, 83 years), hospitalized for decompensated heart failure. Clinical, radiologic, biologic, and ultrasonography data were collected on admission and at discharge. Results The median BNP level on admission was 1,057 pg/mL, and the mean change during hospitalization was -42%. Cardiac death or readmission were independently predicted by both predischarge BNP (best threshold: >360 pq/mL, HR 3.35 [1.94-5.75]) and the change in BNP levels (best threshold: -50%, HR 2.52 [1.59-4.01]). The highest event rate was observed in patients with both a predischarge BNP >= 360 pg/mL and a decrease <50% during hospitalization (HR 5.97 [2.98-11.94] compared with patients with a predischarge BNP <360 pg/mL and a decrease >= 50%, after adjustment for potential confounders). The remaining patients constituted an intermediate risk group (HR 3.13 [1.44-6.77]). Conclusion Predischarge BNP and inhospital BNP change should not be interpreted independently from each other. The highest risk group includes patients with a high predischarge BNP level corresponding to more than the half of the BNP on admission. These patients would benefit from close monitoring for signs of decompensation.
引用
收藏
页码:986 / 991
页数:6
相关论文
共 23 条
  • [11] How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review
    Doust, JA
    Pietrzak, E
    Dobson, A
    Glasziou, PP
    [J]. BRITISH MEDICAL JOURNAL, 2005, 330 (7492): : 625 - 627
  • [12] Prognostic value of plasma brain natriuretic peptide, urea nitrogen, and creatinine in outpatients &gt;70 years of age with heart failure
    Feola, M
    Aspromonte, N
    Canali, C
    Ceci, V
    Giovinazzo, P
    Milani, L
    Quarta, G
    Ricci, R
    Scardovi, AB
    Uslenghi, E
    Valle, R
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (05) : 705 - 709
  • [13] Beta-blockade today: the gap between evidence and practice
    Follath, Ferenc
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2006, 8 (0C) : C28 - C34
  • [14] Influence of age and in-patient care on prescription rate and long-term outcome in chronic heart failure:: a data-based substudy of the EuroHeart Failure Survey
    Hülsmann, M
    Berger, R
    Mörtl, D
    Pacher, R
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2005, 7 (04) : 657 - 661
  • [15] Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure
    Koglin, J
    Pehlivanli, S
    Schwaiblmair, M
    Vogeser, M
    Cremer, P
    von Scheidt, W
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (07) : 1934 - 1941
  • [16] The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe Part 2: treatment
    Komajda, M
    Swedberg, K
    Cleland, J
    Aguilar, JC
    Cohen-Solal, A
    Dietz, R
    Gavazzi, A
    Van Gilst, WH
    Hobbs, R
    Madeira, HC
    Moiseyev, VS
    Preda, I
    Widimsky, J
    Freemanthle, N
    Eastaugh, J
    Mason, J
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 (05) : 464 - 474
  • [17] N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease
    Kragelund, C
    Gronning, B
    Kober, L
    Hildebrandt, P
    Steffensen, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (07) : 666 - 675
  • [18] Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure
    Logeart, D
    Thabut, G
    Jourdain, P
    Chavelas, C
    Beyne, P
    Beauvais, F
    Bouvier, E
    Solal, AC
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (04) : 635 - 641
  • [19] Value of N-terminal pro brain natriuretic peptide in the elderly: data from the prospective Copenhagen Hospital Heart Failure study (CHHF)
    Nielsen, OW
    Kirk, V
    Bay, M
    Boesgaard, S
    Nielsen, H
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (03) : 275 - 279
  • [20] Prognostic value of high plasma brain natriuretic peptide concentration's in very elderly persons
    Ueda, R
    Yokouchi, M
    Suzuki, T
    Otomo, E
    Katagiri, T
    [J]. AMERICAN JOURNAL OF MEDICINE, 2003, 114 (04) : 266 - 270